Skip to content
Back to search results

Children's DLQI (cDLQI) — Dermatology Life Quality Index for Pediatric Patients

Introduced by
Lewis-Jones MS, Finlay AY
Year
1995
Type
Self-report (parent or child proxy)
Family
quality-of-life-pediatric
Font size

What does it do?

The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years.

Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.

The intuition behind the method

Skin diseases in children create burdens distinct from those in adults. A child with psoriasis may worry about swimsuit season or bullying by peers; an adolescent with acne may avoid social activities or develop anxiety. The adult DLQI asks about work and intimate relationships, which are irrelevant to children. cDLQI refocuses quality-of-life assessment on childhood priorities: school attendance, play, friendships, and clothing comfort. This ensures that pediatric treatment efficacy assessment encompasses meaningful outcomes for children and their families.

History

cDLQI was developed and published in 1995 by Lewis-Jones and Finlay at the University of Wales, Cardiff, adapting the adult DLQI (Finlay & Khan, 1992) to the pediatric population. They conducted qualitative research with children and parents to identify age-appropriate quality-of-life domains and generated items reflecting these domains using simplified language. cDLQI was validated in children with diverse skin diseases (atopic dermatitis, psoriasis, vitiligo, acne) and has been translated into numerous languages. It is now the standard quality-of-life measure in pediatric dermatology and is endorsed by major pediatric dermatology societies (American Academy of Dermatology, European Academy of Dermatology and Venereology). In recent years, cDLQI has been increasingly incorporated into pediatric clinical trials of novel dermatological therapies to demonstrate not only clinical efficacy but improved childhood functioning and well-being.

When to use it

cDLQI is indicated in all pediatric dermatology settings, from primary care to specialist centers, for any child with a skin disease affecting quality of life. It is essential in pediatric clinical trials of dermatological treatments to demonstrate not only clinical efficacy but improvement in childhood-relevant quality-of-life domains. cDLQI should be assessed at baseline, 8–12 weeks, and final visit minimum. Periodic assessment (every 4–6 weeks) in clinical practice identifies children at high risk of anxiety, depression, or social isolation due to skin disease and guides psychosocial support or escalation of therapy. cDLQI is particularly valuable in psychologically burdening conditions (acne, alopecia, vitiligo, severe atopic dermatitis) affecting adolescents.

Limitations and considerations

  • Proxy vs. self-report discrepancy; parents may over- or underestimate a child's quality-of-life burden relative to the child's own perception, particularly in adolescents.
  • Age-related interpretation variability; psychometric performance may differ in younger (4–7 years) vs. older children (10–16 years); developmental differences in understanding and response style.
  • No proxy version for adults; parents of children >16 years must transition to adult DLQI, and there is no validated bridging instrument.
  • Subjective recall; children's memory of quality-of-life impact over the past week may be influenced by recent events or current mood.
  • Does not capture objective disease severity; a child with severe eczema but high resilience may score lower than a child with mild disease and poor coping.
  • School-specific items may not apply to all children (e.g., homeschooled or non-school-attending children).
  • Ceiling effects possible in very mild disease; children with minimal QoL impact may score near zero.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Pediatric-specific language and domains; items address childhood-relevant concerns (school, friends, play) rather than work or adult relationships.
  • Validated for children aged 4–16 years; applicable across a broad developmental range with consistent psychometric performance.
  • Brief and simple; 10 items take 3–5 minutes to complete; low respondent burden.
  • Proven responsiveness to treatment; sensitive to clinically meaningful change with topical, phototherapy, and systemic treatments.
  • Proxy and self-report options; parents can complete for younger children; older children can self-report.
  • Widely translated; available in 30+ languages.
  • Endorsed by pediatric dermatology societies and regulatory agencies (FDA, EMA).
  • Strong psychometric properties: internal consistency, test-retest reliability, construct validity across diverse pediatric populations.

Applications

  • Clinical trial endpoint: Co-primary or secondary patient-reported outcome measure in randomized trials of pediatric dermatological treatments, ensuring efficacy encompasses quality-of-life benefit for children and families.
  • Pediatric clinic baseline and monitoring: Assessment at initial visit to identify children with high QoL burden; periodic re-assessment (every 4–6 weeks) during treatment to track improvement and identify psychosocial needs.
  • Epidemiological burden-of-disease studies: Quantifying quality-of-life impact of skin diseases in pediatric populations to inform healthcare priorities and resource allocation.
  • Psychological referral triage: cDLQI scores ≥13 indicate moderate-to-large impact and may warrant concurrent psychological assessment or referral for anxiety/depression screening, particularly in adolescents with acne or alopecia.

How it works

How it works

1

The child (aged 4–16 years) or parent/caregiver completes the 10-item cDLQI questionnaire, typically during a clinic visit or at home. For younger children (4–7 years), parental proxy completion is typically necessary; for older children (8–16 years), direct child self-report is encouraged when feasible. Each item asks 'Over the last week, how much has your skin condition affected...' with response options: 'Not at all' (0), 'A little' (1), 'A lot' (2), 'Very much' (3). Items address: symptoms and feelings (itching, soreness, embarrassment), leisure activities (swimming, sports), school attendance, social interactions with peers, and treatments. Completion takes 3–5 minutes.

Formula
Child or parent completes 10-item questionnaire assessing impact of skin disease over the past week. Items evaluate symptoms and feelings, leisure activities, school or holidays, social functioning, and treatments. Each item uses 0–3 Likert response scale ('not at all'=0 to 'very much'=3).
2

cDLQI scoring is straightforward: sum all 10 item responses (each scored 0–3), yielding a total range of 0–30. Higher scores indicate greater negative impact on quality of life. No weighting, subscales, or adjustments.

Formula
Sum all 10 item scores (each 0–3). Total cDLQI = 0–30. Higher scores indicate greater negative quality-of-life impact.
3

Severity classification: cDLQI 0–1 indicates no or minimal impact on quality of life; 2–6 indicates small impact (mild disruption of daily activities); 7–12 indicates moderate impact (noticeable functional impairment); 13–18 indicates large impact (substantial impact on activities and emotional well-being); 19–30 indicates very large impact (pervasive disruption of childhood functioning). A change of ≥4 points from baseline is considered a clinically meaningful improvement (MCID). The cDLQI is validated in children aged 4–16 years; different psychometric properties may apply outside this age range.

Formula
cDLQI 0–1 = no/minimal impact; 2–6 = small impact; 7–12 = moderate impact; 13–18 = large impact; 19–30 = very large impact. Change of ≥4 points indicates meaningful improvement. cDLQI is validated for children aged 4–16 years.

Common pitfalls

  • Administering without clarifying proxy vs. self-report status; always document whether parent or child completed the questionnaire, as this affects interpretation.
  • Assuming parental and child cDLQI scores are concordant; significant discrepancies are common and clinically meaningful. Investigate disagreement; a child may downplay QoL burden to appear stoic, or a parent may overestimate impact. Both perspectives are valid.
  • Using cDLQI as the sole efficacy measure without objective severity assessment (SCORAD, EASI, PASI); regulatory agencies require both clinical and quality-of-life outcomes.
  • Misinterpreting cDLQI scores as diagnostic; high cDLQI does not indicate psychological disorder; it indicates functional impairment. Psychological assessment is separate.
  • Administering to children <4 years; cDLQI is not validated for infants and toddlers. Use parental or clinician global impression for very young children.
  • Failing to re-assess after treatment initiation; a single baseline cDLQI does not establish responsiveness. Measure at baseline and follow-up (8–12 weeks minimum) to detect change.

Frequently asked questions

Should I use parent report or child self-report for cDLQI?

For children aged 4–7 years, parental proxy completion is typically necessary. For children aged 8–16 years, child self-report is preferred when feasible and the child can read and understand the items. However, both perspectives are valuable: parents assess functional impact (school attendance, family activities); children assess emotional impact (embarrassment, anxiety). Consider administering both and comparing; discrepancies are informative.

What is the MCID for cDLQI?

The minimal clinically important difference (MCID) for cDLQI is ≥4 points; a reduction of ≥4 from baseline indicates meaningful improvement. In clinical practice, improvement from 'moderate' (7–12) to 'small' (2–6) impact category is considered clinically significant.

How does cDLQI differ from adult DLQI?

cDLQI has 10 items and uses simpler language; adult DLQI has 10 items but with different wording focused on adult domains (work, intimate relationships). cDLQI items address school, play, and friendships; DLQI addresses occupational and adult relationship impacts. Use cDLQI for children ≤16 years; transition to DLQI for older adolescents (≥17 years).

Should cDLQI be combined with objective severity measures like SCORAD or EASI?

Yes. cDLQI measures quality-of-life impact; objective measures (SCORAD, EASI, PASI) measure clinical severity. They do not correlate perfectly; a child may have mild clinical disease but high QoL burden due to anxiety or social concerns. Use both in trials and clinical monitoring for a complete picture.

How should I handle disagreement between parent and child cDLQI scores?

Discrepancies are common and clinically meaningful. Parents may overestimate QoL burden or focus on visible disease; children may underestimate due to coping or denial. Discuss the discrepancy with the family: ask the child what aspects of skin disease bother them most, and ask the parent what functional changes they observe. Both perspectives inform treatment planning.

Related methods

Sources

  1. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.

    Open DOI reference
    Copied.
  2. Finlay AY. Quality of life measurement in dermatology: a practical approach. Br J Dermatol. 1997;136(3):305-314.

    Open publication reference
    Copied.